Recombinant Human BID Protein

Beta LifeScience SKU/CAT #: BL-2036NP
BL-2036NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
BL-2036NP: Greater than 95% as determined by reducing SDS-PAGE. (QC verified)

Recombinant Human BID Protein

Beta LifeScience SKU/CAT #: BL-2036NP
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description Recombinant Human BH3-Interacting Domain Death Agonist is produced by our E.coli expression system and the target gene encoding Met1-Asp195 is expressed.
Accession P55957
Synonym BH3-Interacting Domain Death Agonist; p22 BID; BID
Gene Background BH3-Interacting Domain Death Agonist (BID) is a member of the Bcl-2 protein family which regulates outer mitochondrial membrane permeability. BID is a pro-apoptotic member that causes cytochrome c to be released from the mitochondria intermembrane space into the cytosol. Interaction of Bid with Bak causes altered mitochondrial membrane permeability. BID contains only the BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. It is an integrating key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent, and also offer a new strategy for the treatment of acute renal failure associated with ischemia-reperfusion. BID receives direct inputs from a key regulator of the cell cycle arrest/DNA repair machinery (ATM), and therefore is an excellent candidate to coordinate genotoxic stress responses and apoptotic cell death. BID is a novel pro-apoptosis Bcl-2 family protein that is activated by caspase 8 in response to Fas/TNF-R1 death receptor signals. Deletion of BID inhibits carcinogenesis in the liver, although this genetic alteration promotes tumorigenesis in the myeloid cells. This is likely related to the function of BID to promote cell cycle progression into S phase. BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint.
Molecular Mass 21.99 KDa
Apmol Mass 20 KDa, reducing conditions
Formulation Supplied as a 0.2 μm filtered solution of 20mM PB, 100mM KCl, pH 7.4.
Endotoxin Less than 0.1 ng/µg (1 EU/µg) as determined by LAL test.
Purity Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
Biological Activity Not tested
Reconstitution
Storage Store at ≤-70°C, stable for 6 months after receipt. Store at ≤-70°C, stable for 3 months under sterile conditions after opening. Please minimize freeze-thaw cycles.
Shipping The product is shipped on dry ice/polar packs. Upon receipt, store it immediately at the temperature listed below.
Usage For Research Use Only

Target Details

Target Function Induces caspases and apoptosis. Counters the protective effect of BCL2.; Induces caspase activation and apoptosis. Allows the release of cytochrome c.; Induces ICE-like proteases and apoptosis.; Induces ICE-like proteases and apoptosis.; Does not induce apoptosis.; Induces ICE-like proteases and apoptosis.
Subcellular Location Cytoplasm. Mitochondrion membrane. Mitochondrion outer membrane.; [BH3-interacting domain death agonist p15]: Mitochondrion membrane.; [BH3-interacting domain death agonist p13]: Mitochondrion membrane.; [Isoform 1]: Cytoplasm.; [Isoform 3]: Cytoplasm.; [Isoform 2]: Mitochondrion membrane.
Database References

HGNC: 1050

OMIM: 601997

KEGG: hsa:637

STRING: 9606.ENSP00000318822

UniGene: PMID: 29969781

  • The caspase-8/Bid/cytochrome c axis links signals from death receptors to mitochondrial reactive oxygen species production. PMID: 28888620
  • administration of SMAC or BH3 mimetics following short-term paclitaxel treatment could be an effective therapeutic strategy for TNBC, while only BH3-mimetics could effectively overcome long-term paclitaxel resistance PMID: 28187446
  • caspase-10 was dispensable for enhancement of cisplatin/LA-12 and TRAIL combination-induced cell death and stimulation of Bid cleavage PMID: 29182622
  • an oligomeric arrangement of Bid, Bax, and possibly other members of the Bcl-2 family of proteins that form a self-propagating network that permeabilizes the outer-mitochondrial membrane. PMID: 27763642
  • Combined therapy with Seliciclib((R)) and Belinostat((R)) results in eradication of non-small cell lung cancer via apoptosis induction and BID activation. PMID: 27461583
  • Results from genome-wide DNA methylation, functional network analysis and pyrosequencing, show selective CpG sites (NOS1AP, BID, and GABRB1) differentially methylated in smokers and chronic obstructive pulmonary disease patients compared to nonsmokers. PMID: 28416970
  • The adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system can effectively eliminate CD133+ ovarian cancer stem cells, representing a novel therapeutic strategy for the treatment of ovarian cancer. PMID: 27878291
  • MiR-20a-directed regulation of BID in colorectal cancer. PMID: 28004114
  • the results establish that cleavage by caspase 8 and the subsequent association with the outer mitochondrial membrane are two critical events that activate Bid during death receptor-mediated apoptosis. PMID: 27053107
  • The results indicate that BID-independent pathways are responsible for FAS-dependent human islet cell death in Type 1 diabetes. PMID: 26758067
  • The BID-MTCH2 axis regulates the differentiation/apoptosis of stem cells and mitochondrial metabolism. (Review) PMID: 26827940
  • Data suggest, in models of spatial propagation of mitochondrial permeabilization during apoptosis, there appears to be requirement for cooperative signaling involving truncated-BID and ROS (reactive oxygen species) for efficient/ robust propagation. PMID: 26699404
  • this study emphasizes that the coordinated action of hGzmB-activated p53 and GzmB-cleaved Bid is important for GzmB-induced cell death and for cytotoxic lymphocyte/Natural Killer Cell-mediated killing of target cells. PMID: 25404359
  • Tax confers apoptosis resistance to HTLV-1-infected T cells by suppressing the expression of Bim and Bid. PMID: 25522269
  • EG also activated the death receptor-dependent pathway of apoptosis by enhancing the expression of caspases-8, -9, and -3 and the Bcl-2 interacting domain (Bid). PMID: 23109891
  • Inhibition of NANOGP8 or NANOG enhances the cytotoxicity of BH3 mimetics. PMID: 25208882
  • JNK1/2 regulate Bid by direct phosphorylation at Thr59. PMID: 25077544
  • Association of BID gene polymorphisms with proteinuria of immunoglobulin A nephropathy PMID: 24621205
  • The extrinsic apoptotic pathway and BID are activated in adenomas from NSAID-treated patients. NSAIDS only activate BID in cells with APC deficiency and ensuing c-Myc activation. PMID: 25368155
  • Gli1 has a role in regulating the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors PMID: 25253693
  • Bid is phosphorylated during mitosis within its regulatory loop and sensitizes mitochondria for mitochondrial outer membrane permeabilization if mitotic exit is delayed. PMID: 24767991
  • BID expression was found in 53.6% of gastric cancer patients. PMID: 24741635
  • BID is associated with ossification of the posterior longitudinal ligament , and both the G allele of a missense SNP (rs8190315, Ser10Gly) and C allele of a synonymous SNP (rs2072392, Asp60Asp) are risk factors for the development of ossification PMID: 24398548
  • Reduced Bid expression is associated with endometrial cancer. PMID: 24645842
  • FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors. PMID: 23851982
  • structural details on the membrane-associated state of tBid and the functional implications of its membrane-associated BH3 domain PMID: 24158446
  • GrH induced cell death via a Bcl-2-sensitive mitochondrial pathway without direct processing of Bid. PMID: 23352961
  • Caspase-8 binding to cardiolipin in giant unilamellar vesicles provides a functional docking platform for bid PMID: 23418437
  • Three cathepsin D-specific cleavage sites in Bid, Phe24, Trp48, and Phe183, were identified. PMID: 22964611
  • Patients with Parkinson disease have an activated Bid-mediated destructive signal pathway via tumor necrosis factor death receptor I (TNFRI) in the temporal cortex. PMID: 23019260
  • Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier homologue 2 (MTCH2) protein PMID: 22416135
  • Results suggest that truncated BID specifically interacts with phosphatidylserine/cardiolipin and decreases membrane integrity without the aid of other pro-apoptotic proteins. PMID: 22189507
  • 14-3-3 theta/tau and tBID have roles as predictive biomarkers of neoadjuvant chemotherapy resistance in breast cancer PMID: 22115752
  • Decreased apoptosis and expression of Bid, increased level of Bcl-Xl may play some important roles in human jejunal stromal tumors, and Bcl-Xl/Bid ratio may be as a new potentially associated index. PMID: 22339673
  • Bid engages a ROS-dependent, local intermitochondrial potentiation mechanism that amplifies the apoptotic signal as a wave PMID: 22393005
  • critical for controlling cell viability regulated by IFN-alpha in ovarian adenocarcinoma cells PMID: 22130162
  • chronic ethanol increases CYP2E1 activity in adipose, leading to Bid-mediated apoptosis and activation of complement via C1q PMID: 21856753
  • show that due to the high affinity of BAX for BCL-2, BCL-w and A1, and of BAK for BCL-X(L), MCL-1 and A1, only a subset of BH3-only proteins, including BID, could be expected to free BAX or BAK from the antiapoptotic BCL-2 proteins to elicit apoptosis PMID: 21060336
  • a direct role for the BH3 interacting domain death agonist acting at the level of the DNA damage sensor complex to amplify the Atr-directed cellular response to replicative damage PMID: 21113148
  • Data show that the expression of apoptosis proteins caspase-3,-8,-9, and Bid in the RNP of the disc and the SNP was different in each patient. PMID: 21178828
  • Cells stabilize active caspase-8 on the mitochondria in order to specifically target mitochondria-associated BID. PMID: 21072056
  • When tBid was introduced into the HIV-1 LTR-based, Tat- and Rev-dependent transgene expression vector pLRed(INS)2R, very efficient induction of apoptosis was observed within 24 hours,but only in the presence of both HIV-1 regulatory proteins Tat and Rev. PMID: 21223573
  • tBID and other BCL-2 proteins have a role in osteosarcoma [commentary] PMID: 19029793
  • In rheumatoid arthritis fibroblast like synovial cells phosphorylation of Akt protects against Fas-induced apoptosis through inhibition of Bid cleavage. PMID: 20187936
  • The interface between apoptosis initiation and execution by determining caspase-8 activation, Bid cleavage and mitochondrial engagement (onset of mitochondrial depolarisation) in individual HeLa, was analysed. PMID: 20356928
  • Data revealed that the level of tBid expression in breast cancer cells were nearly 11 times more than normal cells because of the cancer specific promoters. PMID: 19918914
  • Bid may serve as a critical integrating factor of the death receptor and mitochondrial pathway in alpha-tocopheryl succinate-mediated apoptosis. PMID: 19640637
  • tBid-induced permeabilization of the outer membrane permits release of cytochrome c and Smac/DIABLO from all domains of intermembrane space. tBid-induced loss of DeltaPsi(m) occurs after cytochrome c release and reflects impairment of oxidative metabolism PMID: 11741882
  • Cytochrome c release upon Fas receptor activation on translocation of full-length bid PMID: 11790791
  • FAQs

    Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

    Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

    Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

    Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

    Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

    Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

    To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.

    Recently viewed